Cancer

Circulogene Launches Tissue-Based Genomic Profiling Assay for Solid Tumors

OncoGenDx analyzes 335 DNA genes and 72 RNA genes using next-generation sequencing technology to support treatment decisions.

Cancer

Large Clinical Trial to Assess Nasal Swab Test for Guiding Lung Cancer Care

The 2,400-patient study evaluates the Percepta Nasal Swab test's ability to guide management decisions for patients with lung nodules.

Cancer

Personalis MRD Test Shows Superior Sensitivity in Lung Cancer Trial

The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca's NeoADAURA study.

Colorectal Cancer Screening Surges 62% Among Adults 45-49, Driving Early-Stage Diagnoses

Aug 15, 2025 | Cancer

Two new American Cancer Society studies reveal significant increases in colorectal cancer...

Three Boston Institutions Launch Precision Genomics Initiative for Pediatric Cancer Testing

Aug 15, 2025 | Cancer

Dana-Farber Cancer Institute, Boston Children’s Hospital, and Broad Clinical Labs form BrightSeq collaborative to develop novel clinical diagnostic assays for rare pediatric cancers.

At-Home Cervical Cancer Screening Now Available, Starting in California

Aug 14, 2025 | Cervical (HPV)

This marks the first time a US Food and Drug Adminstration-authorized self-collection device is available for at-home cervical cancer screening in the US.

Test Gains Medicare Coverage for Early-Stage Breast Cancer Recurrence Monitoring

Aug 12, 2025 | Breast

Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.

CyPath Lung Flags Early-Stage Cancer Overlooked by Previous Tests

Aug 8, 2025 | Lung Cancer

A case study shows how the noninvasive test detected Stage 1A mucinous adenocarcinoma in a high-risk patient whose previous tests and follow-up scans had suggested a low probability of cancer.

Declining Cancer Screening Rates Prompt Interest in New Detection Methods

Jul 28, 2025 | Cancer

A survey indicates a decline in cancer screening rates, contrasted by growing interest in at-home and multi-cancer early detection tests.

LIMA1-Alpha Protein Predicts Head and Neck Cancer Patients who Can Be Cured with Surgery Alone

Jul 24, 2025 | Unknown Origin & Other Cancer Types

Researchers have developed an LIMA1-alpha assay that can identify head and neck cancer patients who can be cured with surgery alone.

Pancreatic Cancer Has Genetic Early Warning System

Jul 23, 2025 | Pancreatic

Researchers have discovered how cellular stress and inflammation drive pancreatic cancer progression via the STAT3-ITGB3 pathway.

Blood Cancers Could Be Detected with Breath Test

Jul 23, 2025 | Cancer

Researchers have shown that molecules in exhaled breath can help detect blood cancer, paving the way for a lnon-invasive breathalyzer test.

Innovation Key to Reversing Decline in Routine Cancer Screenings

Jul 21, 2025 | Cancer

A new survey reveals declining cancer screening rates among U.S. adults, but shows strong interest in innovative screening methods.

Thyroid Cancer Diagnosis Redefined with AI-Powered Biomarker

Jul 18, 2025 | Unknown Origin & Other Cancer Types

A new study introduces a dynamic biomarker system to improve early risk detection in differentiated thyroid carcinoma (DTC).

microRNAs Emerge as Biomarkers, Diagnostic Tools in Soft Tissue Sarcoma

Jul 18, 2025 | Cancer

An highlights the growing role of microRNAs in soft tissue sarcoma (STS) research, emphasizing their promise as diagnostic biomarkers.

Bronchoscopic Lung-Biopsy Techniques Have Fewer Complications

Jul 11, 2025 | Lung Cancer

New multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.

VieCure Expands Precision Oncology Ecosystem Through Partnership with Guardant Health

Jul 10, 2025 | Cancer

VieCure has partnered with Guardant Health to integrate Guardant’s precision oncology tests into the AI-powered Halo Intelligence platform.

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Jul 9, 2025 | Colorectal

Personalis has expanded and extended its partnership with Tempus AI to include colorectal cancer in their NeXT Personal MRD test.

Category: Cancer

Cancer

Cancer

Cancer